Literature DB >> 18363999

Polarized immune responses differentially regulate cancer development.

Magnus Johansson1, David G Denardo, Lisa M Coussens.   

Abstract

Tumor-associated immune responses assert varied responses toward developing neoplasms that can either act to eradicate malignant cells via engagement of potent cytotoxic programs or alternatively enhance tumor growth through release of multifunctional pro-tumor mediators. Seemingly paradoxical, these disparate activities reflect a continuum of polarization (or activation) states possible for distinct leukocyte subsets that demonstrate tissue, organ, and tumor selectivity. Herein, we review clinical and experimental studies investigating cellular and molecular mechanisms utilized by neoplastic tissues to alternatively polarize immune responses that favor either pro- or anti-tumor immunity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18363999      PMCID: PMC2494984          DOI: 10.1111/j.1600-065X.2008.00600.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  93 in total

Review 1.  Cancer despite immunosurveillance: immunoselection and immunosubversion.

Authors:  Laurence Zitvogel; Antoine Tesniere; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2006-09-15       Impact factor: 53.106

Review 2.  Th17: an effector CD4 T cell lineage with regulatory T cell ties.

Authors:  Casey T Weaver; Laurie E Harrington; Paul R Mangan; Maya Gavrieli; Kenneth M Murphy
Journal:  Immunity       Date:  2006-06       Impact factor: 31.745

3.  Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells.

Authors:  Estelle Bettelli; Yijun Carrier; Wenda Gao; Thomas Korn; Terry B Strom; Mohamed Oukka; Howard L Weiner; Vijay K Kuchroo
Journal:  Nature       Date:  2006-04-30       Impact factor: 49.962

4.  Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation.

Authors:  Yoshikatsu Kaneko; Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Science       Date:  2006-08-04       Impact factor: 47.728

Review 5.  Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms.

Authors:  Gregg J Silverman
Journal:  Arthritis Rheum       Date:  2006-08

Review 6.  Novel antibody-based therapy for acute lymphoblastic leukaemia.

Authors:  Nicola Gökbuget; Dieter Hoelzer
Journal:  Best Pract Res Clin Haematol       Date:  2006       Impact factor: 3.020

Review 7.  Humoral immunity, inflammation and cancer.

Authors:  Ting-Ting Tan; Lisa M Coussens
Journal:  Curr Opin Immunol       Date:  2007-02-02       Impact factor: 7.486

8.  IL-23 promotes tumour incidence and growth.

Authors:  John L Langowski; Xueqing Zhang; Lingling Wu; Jeanine D Mattson; Taiying Chen; Kathy Smith; Beth Basham; Terrill McClanahan; Robert A Kastelein; Martin Oft
Journal:  Nature       Date:  2006-05-10       Impact factor: 49.962

9.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

Review 10.  Toll-like receptors in systemic autoimmune disease.

Authors:  Ann Marshak-Rothstein
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

View more
  80 in total

1.  Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response.

Authors:  Josie Ursini-Siegel; Sean Cory; Dongmei Zuo; William R Hardy; Elton Rexhepaj; Sonya Lam; Babette Schade; Karin Jirstrom; Eva Bjur; Ciriaco A Piccirillo; David Denardo; Lisa M Coussens; Donal J Brennan; William M Gallagher; Morag Park; Tony Pawson; Michael Hallett; William J Muller
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

Review 2.  Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology.

Authors:  Nobuyoshi Hiraoka
Journal:  Int J Clin Oncol       Date:  2010-10-06       Impact factor: 3.402

Review 3.  Serologic laboratory findings in malignancy.

Authors:  Félix Fernández Madrid; Marie-Claire Maroun
Journal:  Rheum Dis Clin North Am       Date:  2011-11       Impact factor: 2.670

4.  Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.

Authors:  Qingfei Wang; Shau-Hsuan Li; Hai Wang; Yi Xiao; Ozgur Sahin; Samuel W Brady; Ping Li; Hailiang Ge; Elizabeth M Jaffee; William J Muller; Gabriel N Hortobagyi; Dihua Yu
Journal:  Cancer Res       Date:  2012-07-06       Impact factor: 12.701

5.  A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II.

Authors:  Nrupen A Bhavsar; Jay H Bream; Alan K Meeker; Charles G Drake; Sarah B Peskoe; Djeneba Dabitao; Angelo M De Marzo; William B Isaacs; Elizabeth A Platz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-08-22       Impact factor: 4.254

Review 6.  Immunobiology of hepatocarcinogenesis: Ways to go or almost there?

Authors:  Pavan Patel; Steven E Schutzer; Nikolaos Pyrsopoulos
Journal:  World J Gastrointest Pathophysiol       Date:  2016-08-15

7.  LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment.

Authors:  Rong Fu; Yi-Wei Zhang; Hong-Mei Li; Wen-Cong Lv; Li Zhao; Qing-Long Guo; Tao Lu; Stephen J Weiss; Zhi-Yu Li; Zhao-Qiu Wu
Journal:  Br J Pharmacol       Date:  2018-06-03       Impact factor: 8.739

Review 8.  Inflammation and stem cells in gastrointestinal carcinogenesis.

Authors:  Michael Quante; Timothy Cragin Wang
Journal:  Physiology (Bethesda)       Date:  2008-12

Review 9.  Lymphocytes in cancer development: polarization towards pro-tumor immunity.

Authors:  Brian Ruffell; David G DeNardo; Nesrine I Affara; Lisa M Coussens
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-11       Impact factor: 7.638

Review 10.  Tumor-host interactions: the role of inflammation.

Authors:  Marie-Aude Le Bitoux; Ivan Stamenkovic
Journal:  Histochem Cell Biol       Date:  2008-10-25       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.